A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)

Clinical trial NCT07592819 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07592819
Sponsor: Institut Paoli-Calmettes
Status: NOT_YET_RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

Pancreas Adenocarcinoma (MSI-H)Pancreatic Cancer Resectable

Start date: 2026-05-01
Primary completion: 2030-05-01
Enrollment: 367

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.